source
- Cadrenal Therapeutics launches strategic review to explore sale or partnership for its late-stage cardiology pipelineCadrenal Therapeutics, a heart-focused biotech, announced a strategic review of its late-stage cardiology pipeline, seeking to offload assets or the entire company. The board is evaluating options…
- Cerevance reports positive Phase 3 results for Parkinson’s drug solengeprasCerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…